Aptevo Therapeutics Inc. $APVO

By Microcap Ledger desk · CIK 0001671584

Facts as of Oct 11, 2026, 08:19 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: Seattle, WA
Fiscal year end: December 31
Shares outstanding: 1,801,970 [10-Q 2026-08-14]
as of 2026-08-14

Sources: [10-K 2026-03-26]

What the company doesAI summary of filing

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing immunotherapy candidates for cancer treatment. The company has two clinical-stage product candidates—mipletamig, a bispecific T cell engager for acute myeloid leukemia in combination with standard chemotherapy, and ALG.APV-527, a bispecific antibody targeting 4-1BB and 5T4 for solid tumors—along with six preclinical candidates, all designed using its proprietary ADAPTIR and ADAPTIR-FLEX protein technology platforms. The company generates no product revenue and is funded through research and development activities; it may pursue collaborations and partnerships to advance its pipeline. [10-K 2026-03-26]

Segments: Mipletamig (CD123xCD3 T cell engager for AML), ALG.APV-527 (4-1BB/5T4 bispecific for solid tumors), ADAPTIR platform, ADAPTIR-FLEX platform

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$13.05M	−$13.42M	$9.80M	[10-Q 2026-08-14]
FY ended Dec 2025	—	−$25.97M	−$25.59M	$21.62M	[10-K 2026-03-26]
FY ended Dec 2024	—	−$24.13M	−$23.79M	$8.71M	[10-K 2026-03-26]

Quarterly cash burn: −$6.71M
Cash runway Estimate: ~4.4 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-07	18,512,084	[10-Q 2024-11-07]
2025-02-14	1,458,445	[10-K 2025-02-14]
2025-05-15	8,109,290	[10-Q 2025-05-15]
2025-08-11	3,287,918	[10-Q 2025-08-11]
2025-11-06	16,850,494	[10-Q 2025-11-06]
2026-03-26	1,181,725	[10-K 2026-03-26]
2026-05-13	1,246,105	[10-Q 2026-05-13]
2026-08-14	1,801,970	[10-Q 2026-08-14]

Shelf registration: S-1 filed 2026-08-21; declared effective 2026-09-02 [S-1 2026-08-21]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-05-22. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2025-05-22	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-05-22]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-08-06	Harsanyi Zsolt	exercise	400	—	[4 2026-08-10]
2026-08-06	Lamothe Jeffrey G.	exercise	961	—	[4 2026-08-10]
2026-08-06	Taylor Daphne	exercise	638	—	[4 2026-08-10]
2026-08-06	Kwon Soyoung	exercise	638	—	[4 2026-08-10]
2026-08-06	Huebner Dirk	exercise	638	—	[4 2026-08-10]
2026-08-06	Huebner Dirk	other	156	$4.07	[4 2026-08-10]
2026-08-06	Grant Grady Iii	exercise	400	—	[4 2026-08-10]
2026-08-06	White Marvin L	exercise	1,666	—	[4 2026-08-10]
2026-08-06	White Marvin L	other	406	$4.07	[4 2026-08-10]
2026-08-06	Abdun-Nabi Daniel	exercise	400	—	[4 2026-08-10]
2026-07-17	White Marvin L	exercise	1	—	[4 2026-08-10]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-09-24	8-K	Other events
2026-09-23	8-K	Shareholder vote results
2026-09-03	424B4	Prospectus or prospectus supplement
2026-09-03	8-K	Other events
2026-08-31	DEF 14A	Proxy statement
2026-08-21	PRE 14A	Proxy statement
2026-08-21	S-1	Registration statement
2026-08-21	8-K	Shareholder vote results
2026-08-14	13G/A	Beneficial ownership report (5%+ holder)
2026-08-14	10-Q	Quarterly report
2026-08-14	8-K	Results of operations
2026-08-13	8-K	Material agreement entered; Unregistered sale of equity; Other events

Facts as of Oct 11, 2026, 08:19 AM UTC. Small caps move fast; check the latest filings.